Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application

被引：38

作者：

Garaci, E ^{[1
]}

Pica, F ^{[1
]}

Rasi, G ^{[1
]}

Favalli, C ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy

来源：

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 2000年 / 22卷 / 12期

关键词：

cancer; immunotherapy; thymosin alpha 1;

D O I：

10.1016/S0192-0561(00)00075-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue. (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd. All rights reserved.

引用

页码：1067 / 1076

页数：10

共 48 条

[1] IFN-β partially counteracts inhibition of natural killer activity induced by some antitumor agents [J].

Allavena, P ;

Giardina, G ;

Sen, S ;

Colella, G ;

Broggini, M ;

D'Incalci, M .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (02) :87-93

[2] THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].

BARON, S ;

TYRING, SK ;

FLEISCHMANN, WR ;

COPPENHAVER, DH ;

NIESEL, DW ;

KLIMPEL, GR ;

STANTON, GJ ;

HUGHES, TK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383

[3]

FAVALLI C, 1985, CANCER IMMUNOL IMMUN, V20, P189

[4] SYNERGISTIC EFFECT OF THYMOSIN ALPHA-1 AND ALPHA-BETA-INTERFERON ON NK ACTIVITY IN TUMOR-BEARING MICE [J].

FAVALLI, C ;

MASTINO, A ;

JEZZI, T ;

GRELLI, S ;

GOLDSTEIN, AL ;

GARACI, E .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1989, 11 (05) :443-450

[5]

FAVALLI C, 1992, COMBINATION THERAPIES, P275

[6] TUMOR-INHIBITION BY INTERLEUKIN-2 AT THE TUMOR HOST INTERFACE [J].

FORNI, G ;

GIOVARELLI, M ;

SANTONI, A ;

MODESTI, A ;

FORNI, M .

BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 865 (03) :307-327

[7] COMBINATION TREATMENT USING THYMOSIN ALPHA-1 AND INTERFERON AFTER CYCLOPHOSPHAMIDE IS ABLE TO CURE LEWIS LUNG-CARCINOMA IN MICE [J].

GARACI, E ;

MASTINO, A ;

PICA, F ;

FAVALLI, C .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (03) :154-160

[8] Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a [J].

Garaci, E ;

Lopez, M ;

Bonsignore, G ;

DellaGiulia, M ;

DAprile, M ;

Favalli, C ;

Rasi, G ;

Santini, S ;

Capomolla, E ;

Vici, P ;

DiLauro, L .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2403-2405

[9]

GARACI E, 1989, B NEW YORK ACAD MED, V65, P111

[10] ANTITUMOR EFFECT OF THYMOSIN ALPHA-1/INTERLEUKIN-2 OR THYMOSIN ALPHA-1/INTERFERON ALPHA,BETA FOLLOWING CYCLOPHOSPHAMIDE IN MICE INJECTED WITH HIGHLY METASTATIC FRIEND-ERYTHROLEUKEMIA CELLS [J].

GARACI, E ;

PICA, F ;

MASTINO, A ;

PALAMARA, AT ;

BELARDELLI, F ;

FAVALLI, C .

JOURNAL OF IMMUNOTHERAPY, 1993, 13 (01) :7-17

← 1 2 3 4 5 →